SCHEMBL20912337

SCHEMBL20912337

O=c1[nH]cnc2c(-c3ccc(OCCCO)cc3)cn(-c3ccccc3)c12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.49
SRC P12931 2/20 0.47
PKM P14618 1/20 0.46
BRD4 O60885 2/20 0.44
LMNA P02545 3/20 0.41
GAA P10253 1/20 0.41
HTT P42858 1/20 0.41
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
FGFR1 P11362 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
HRH3 Q9Y5N1 1/20 0.37
XDH P47989 1/20 0.37
MYC P01106 1/20 0.37
PRKAB2 O43741 1/20 0.36
PRKAG1 P54619 1/20 0.36
PRKAA2 P54646 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20912340 0.96 MAPT (0.51) MAPTSRCPKMBRD4LMNA
SCHEMBL20912341 0.87 MAPT (0.49) MAPTSRCPKMBRD4LMNA
SCHEMBL20911641 0.85 SRC (0.48) MAPTSRCPKMBRD4LMNA
SCHEMBL20911920 0.85 MAPT (0.49) MAPTSRCPKMBRD4LMNA
SCHEMBL20898350 0.85 ADORA3 (0.47) MAPTSRCPKMBRD4LMNA
SCHEMBL20912016 0.85 MAPT (0.49) MAPTSRCPKMBRD4LMNA
SCHEMBL20912017 0.85 MAPT (0.49) MAPTSRCPKMBRD4LMNA
SCHEMBL20911708 0.85 MAPT (0.49) MAPTSRCPKMBRD4LMNA
SCHEMBL20912038 0.84 MAPT (0.56) MAPTSRCPKMBRD4LMNA
SCHEMBL8819526 0.84 SRC (0.64) MAPTSRCPKMBRD4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795169-B2 MAP4K4 inhibitors IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-10-24 US disclosed
US-11795169-B2 MAP4K4 inhibitors IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-10-24 US disclosed
US-20200339583-A1 MAP4K4 INHIBITORS IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2020-10-29 US disclosed
WO-2019073253-A1 MAP4K4 INHIBITORS IMPERIAL INNOVATIONS LIMITED (GB) 2019-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339583-A1 MAP4K4 INHIBITORS MAP4K4, MAP4K2, MAP4K5 MAPT 315/4885SRC 594/4885PKM 260/4885
US-11795169-B2 MAP4K4 inhibitors MAP4K4, MAP4K2, MAP4K5 MAPT 315/4885SRC 594/4885PKM 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.